Abstract Although tumor cells are found in the blood early after tumorigenesis, dissemination through the lymphatic system and in particular the formation of lymph node metastases has long been considered to be a driving force behind the formation of secondary tumors in distant vital organs. Contemporary experimental observations and clinical trial results suggest that this may not be the case. In this review we survey the evidence for both points of view, and examine the hypothesis that the prognostic relevance of lymph node metastases may lie in their ability to indicate that primary tumors are producing soluble factors that have the potential to promote metastasis at these distant sites, for example by releasing tumor cells from dormancy. Furthermore, the interconnectivity between the lymphatic and blood circulatory systems underscores the relevance of the analysis of the properties of circulating and disseminated tumor cells for prognostic evaluation, patient stratification and understanding the biology of metastasis. We therefore give an overview of the current state of the art in this field.
Introduction
Dissemination of tumor cells through the vasculature of the blood and lymphatic system represents the route the vast majority of tumor cells take during metastatic spread [1] . These two vascular systems are intimately connected, reflecting their related functions. The physiological function of the lymphatic system is to return interstitial fluid to the blood vascular compartment, to transport nutrients from the gut to the circulation, to expose B and T lymphocytes to foreign antigens, thereby eliciting humoral antibodies from B lymphocytes and cytotoxic cytokines from T lymphocytes. Its function in the innate and adaptive immune systems is mediated by lymph nodes, porous organs that are interposed in the lymph flow of the lymphatic vessels to temporarily capture antigens for lymphocyte analysis and organization of antibody and cytokine production. Lymph nodes are dynamic organs housing lymphocytes that arrive, analyze antigens and then leave to recirculate for host immunocompetence. The presence of lymph nodes along the lymphatic vasculature is a major difference between the blood and lymphatic circulatory systems, and is an important site of metastasis formation.
The anatomy of the lymphatic system and its relationship with the blood vasculature reflects its physiological role [2] . Anastomoses between blood and lymphatic are found in the lymph nodes in the form of high endothelial venules (HEVs), as well as between larger collecting vessels such as the anastomosis between the thoracic duct and the jugular vein. Although transit between the blood and lymphatic system via HEVs remains poorly investigated, anastomoses not only facilitate the physiological function of the lymphatic system but also in principle provide conduits through which circulating tumor cells can transit from one type of vasculature to the other. The degree to which this happens and its relevance to metastasis formation has major ramifications not only for our understanding of the process of metastasis, but also for clinical strategies to combat metastatic disease. In this review we examine what we know about the relationship between lymphogenous and hematogenous cancer spread, and examine some of the clinical implications of these observations, focusing on the ability of tumor cells to remain dormant for many years before giving rise to overt metastases, as well as the clinical and biological relevance of circulating tumor cells (CTCs) in the blood.
Dissemination through the lymphatics: just a parallel side road or a favoured highway?
A variety of observations provide direct evidence that tumor cells circulate in both the blood and lymphatic systems. CTCs can be readily isolated from the blood of cancer patients, and in histological sections the presence of tumor cells in lymphatic vessels is regularly observed. The work of Bernard and Edwin Fisher provided first experimental evidence for an interconnectivity between these two routes of dissemination. Using 51 chromium to label tumor cells and track their migration in vivo, they concluded that disseminating tumors interchangeably circulate in the blood and lymphatic vasculature [3] [4] [5] . Although these results may be subject to artifact caused by release of 51 Cr and uptake by other cells [6] , our own unpublished work using genetic marking of tumor cells as they traffic through the lymphatics indicates that a substantial proportion of metastases in the lung are seeded by tumor cells that have trafficked through the lymphatic system (Sleeman and Grau, in preparation).
Lymph nodes were suggested in the early literature to act as filters that impeded further dissemination through the lymphatic system, and to destroy CTCs through their immune function. However, more recent observations have largely discounted these notions [7] . Indeed, the primary tumor suppresses immune responses in the draining lymph nodes [8] . Although tumor cells may be temporarily arrested in the lymph nodes as they pass through, most recent studies suggest that the majority of tumor cells can circulate through the lymph nodes [3] [4] [5] [9] [10] [11] [12] [13] . Those that are mechanically entrapped can go on to form lymph node metastases. Once overt lymph node metastases form and the lymphatic architecture is compromised, lymphatic flow is blocked. The formation of collaterals around the blocked lymph nodes can re-establish lymphatic flow [14] . Together, these observations suggest that during tumor progression the interconnected circulation between the blood and lymphatic vasculature remains intact until overt lymph node metastases form, and can be re-established through the formation of collaterals.
Interconnectivity between the blood and lymphatic vasculature routes of tumor dissemination is also relevant to the recently suggested concept of self-seeding. CTCs can be derived from both primary tumors and their metastases. Observations in experimental animals suggest that cells circulating in the vasculature may not only seed metastases, but can also return to the primary tumor and contribute to primary tumor growth [15] and maybe even local relapse. If this is confirmed in cancer patients, it would represent a paradigm shift in understanding the relevance of CTCs to tumor growth and metastasis.
Thus the lymphatic system acts an additional route of dissemination for tumor cells over and above that provided by the blood vasculature, but its lymph nodes also provide sites for metastasis formation that is not paralleled in the blood circulatory system. Clinical and experimental observations concerning lymph node metastasis formation have been interpreted to suggest that passage of tumor cells through the lymphatics may act to promote metastasis formation in a manner that is not afforded by passage of tumors cells through the blood circulation. In the following we review the evidence for and against this notion.
Evidence that the lymphatic system makes a decisive contribution to metastasis formation in distant organs that is not afforded by the blood vasculature For many carcinomas, the presence of metastases in lymph nodes is often the first indication that tumors have begun to spread, and is a strong predictor of poor outcome. Accordingly, the metastatic status of regional lymph nodes is of central prognostic importance in the majority of staging schemes. Assessment of the presence of tumor cells in the first or ''sentinel'' lymph node that drains a primary tumor has become established as an important guide for the course of post-operative therapy. The biology behind these observations has been traditionally interpreted in the context of the notion of the metastatic cascade. On the basis of clinical observations and autopsy studies it is widely held that metastasis occurs in a step-wise process, with metastases forming in lymph nodes that then themselves in turn seed further metastases in distant sites [7] . Experimental support for this notion comes from studies in which primary tumors but not lymph node metastases are removed, and metastases subsequently form in distant organs [16, 17] . As tumor cells access the lymphatic vasculature relatively easily and are not subject to the harsh hemodynamic conditions of the blood circulation, it has been suggested that lymph node metastases act as bridgeheads for further metastatic spread by selecting and expanding tumor cell populations that possess some of the properties required for the more stringent formation of metastases in distant organs [18] .
Recent evidence suggests that entry of tumor cells into the lymphatic system as a means of accessing the circulatory system is promoted in a way that is not found for the blood vasculature. In the context of cancer, tumor-induced angiogenesis and lymphangiogenesis both serve to increase the density of capillaries into which disseminating tumor cells can invade. However, tumor cells may be especially attracted to the lymphatics. Chemokines produced by the lymphatic capillaries can act as a chemotactic stimulus for tumor cells that express the corresponding receptor [19, 20] . Furthermore, when tumor cells produce chemoattractive proteins that act in an autocrine manner, the flow of lymphatic fluid around the cell can elicit directed migration to the lymphatics in a process called autologous chemotaxis [21] .
Once in the lymphatic environment, additional functions specific to the lymphatic system may act on tumor cells to promote metastasis in lymph nodes. In his landmark paper, Paget states ''how favourable the lymph glands are to the growth and spread of cancer'' [22] . Accordingly, continual passaging of poorly metastatic experimental tumors as lymph node metastases first increases their ability to form lymph node metastases, then promotes metastasis formation in distant organs [23, 24] , suggesting that the lymph node microenvironment may condition tumor cells and render them more metastatically competent. At the molecular level, chemokines expressed in the lymph nodes may promote lymph node metastasis formation by disseminating tumor cells expressing the cognate receptor [25] [26] [27] .
In summary, these observations are consistent with the notion that entry into and passage through the lymphatic system offers selective advantages to disseminating tumor cells, and promotes metastasis formation either by fostering access to the circulatory system, by increasing the metastatic proclivity of the tumor cells, or by providing a metastatic bridgehead in the lymph nodes that facilitates metastasis formation in distant organs. Such as notion provides a ready explanation for the prognostic importance of lymph node metastases, but also has clinical implications. An important conclusion that arises from this concept is that removal of the lymph nodes that drain primary tumors should give a survival advantage to cancer patients, because metastatic cells in the lymph nodes would be removed, interrupting the metastatic cascade and blocking further metastatic spread. This is the theoretical basis on which elective removal of regional lymph nodes was developed in the last century, stimulated by Halstead's radical mastectomy for the treatment of breast cancer [28] .
Evidence against a decisive role for the lymphatic system in a metastatic cascade that leads to metastasis formation in distant organs
The notion that the lymphatic system plays a central role in a metastatic cascade leading to distant organ metastasis formation has been undermined over recent years at a number of levels. Lymph nodes do not represent an obligatory site of metastasis formation prior to metastasis formation in other organs. Even for breast cancer, a disease which frequently gives rise to lymph node metastases, a quarter of all patients with small tumors who develop distant metastases do not have metastases in their lymph nodes [29] . Other types of cancer and especially sarcomas rarely give rise to lymph node metastases, but nevertheless readily form secondary tumors in other organs [30, 31] . Furthermore, as pointed out above, the lymphatic system appears to provide an unhindered route for disseminating tumor cells until the formation of large overt metastases. Once such large nodal metastases form, lymph flow may cease until collaterals redirect lymphatic fluid flow around the blocked lymph node. This would not seem compatible with dissemination from established lymph node metastases being responsible for the seeding of metastasis in distant organs. Moreover, analysis of tumor growth rates at primary and secondary sites indicates there is simply not enough time in the life of a cancer patient for a metastasis in a lymph node to seed a fulminant metastasis in another organ [32] . Finally, the notion that the lymph node is an important component in a metastatic cascade relies on assumptions that do not stand up in the light of recent observations. For example, seeding of metastases in distant organs would need to be a late event in the development and progression of tumors if lymph node metastases were to be the source of the metastatic founder cells of distant organ metastases. In fact, the evidence points to the seeding of distant organ metastases very early after tumorigenesis [33] . Additionally, differentiated thyroid cancers in young, low risk patients are marked by extensive lymph node metastases in over 75 % of patients but the 20 year survival is 99 %, indicating that the nodal route of spread is quite separate from the vascular route. This lack of relationship of node metastases to survival is also seen in carcinoids of the GI tract and islet cell cancers of the pancreas.
The most telling evidence against the notion of lymph node metastases acting as an important component of a metastatic cascade comes from analysis of the clinical efficacy of the removal of regional lymph nodes in long term randomized clinical trials. As we have recently reviewed, the striking take home message from the majority of the largest and most reliable studies is that for many types of cancer there is little if any impact on patient survival whether or not regional lymph nodes are removed, even where a significant proportion of the patients subsequently develop metastases in lymph nodes that are left in situ [1] . Despite the lack of impact on survival, the presence of lymph node metastases in these clinical trials was nevertheless found to be prognostically relevant. Thus a picture emerges in which the formation of metastases in regional lymph nodes acts as an indicator of an increased probability of metastasis formation in vital organs, but does not contribute to the seeding of these distant metastases.
Lymph node metastases as indicators of the production of systemic instigators of stromal progression by primary tumors Why do lymph node metastases act as indicators of poor prognosis, yet their removal does not affect patient survival? As pointed out above, there is evidence that the lymph node microenvironment can condition tumor cells, rendering them more metastatically competent. If this conditioning promotes both lymph node and distant organ metastasis formation (as seems to be the case), then the presence of lymph node metastases could indicate that there is an enhanced probably that CTCs were metastatically conditioned in the lymph node microenvironment and have seeded metastases elsewhere, prior to the formation of overt lymph node metastases. In this case, removal of the lymph node metastasis would not affect prognosis, but the presence of the lymph node metastasis would be prognostically relevant. Furthermore, as mentioned previously, lymphatic vessels represent a relatively easy entry point into the circulatory system, and a number of mechanisms have been uncovered that actively attract disseminating tumor cells to enter the lymphatic vasculature. These mechanisms would serve to increase both the incidence of lymph node metastasis, but also the number of CTCs in the blood and lymphatic system that could seed metastases at distant sites. Indeed, the number of CTCs in the blood correlates with poor prognosis (see below). In this scenario, lymph node metastases would act as indicators that substantial numbers of CTCs have trafficked via the lymphatics prior to the formation of the lymph node metastasis, thus increasing the number of circulating CTCs and thereby increasing the probability of distant organ metastasis. Again, removal of lymph node metastases would not have any effect on prognosis.
A further explanation can possibly be derived from the concept of dormancy. When tumor cells first disseminate and lodge at distant sites, they either grow, die or remain dormant [34] . A few may go on to grow out as overt metastases, and may require a specific niche to do so [35] . Dormant tumor cells exist as single cancer cells or small tumor cell masses invisible by routine imaging procedures, and ten or more years can elapse before the dormant tumor cells are re-activated and form an overt metastasis [36] . While genetic changes in the tumor cells can contribute to release from dormancy, most evidence points to microenvironmental control of dormancy that is relieved by changes in the stromal constituents around the dormant cells in a process we have termed stromal progression [35] .
The transplantation literature gives unique insights into cancer cell metastatic distribution and dormancy. In renal transplantation from patients who previously had a melanoma, 21 recipients developed melanoma and 11 died. Recipients who did not die had withdrawal of immunosuppression and rejected the kidney but also the transplanted melanoma [37] . In liver, lung and heart transplantation, tumor transmission is almost 50 percent if the donor had ever had an invasive cancer from cervix, kidney, liver, lung, prostate, angiosarcoma, choriocarcinoma, or even glioblastoma [38] . A donor not known to have cancer before death and donation caused a small-cell lung cancer in the recipient, and genetic analysis showed that this transplanted cancer came from the donor, even though there was no detectable cancer [39] . Thus even cancers that are not clinically apparent shed cells that can be transmitted. A donor who had been successfully treated for melanoma 16 years previously donated both kidneys were after death from trauma. Both recipients developed metastatic melanoma from melanoma cells transplanted with the kidneys [40] . So not only are metastatic cancer cells very common and widely distributed but they survive for long periods of time. Accordingly, in a report from M.D. Anderson of patients 7-22 years after mastectomy with no evidence of disease, over a third had cancer cells detected in circulation consistent with cancer cell dormancy [41] .
Tumor cells can also disseminate to and lie dormant in lymph nodes. Micrometastases in draining lymph nodes that are not surgically removed can eventually outgrow years later [2] . In a genetic study on multiple lymph node metastases taken from the same breast cancer patient, hierarchical clustering of allelic imbalances in the lymph node metastases showed divergent genomic aberrations between them, as well as with the primary tumor, indicating that the metastases were seeded at different times and went through a period dormancy before growing out as metastases [42] .
Soluble factors produced by primary tumors have been implicated in the instigation of stromal progression at future sites of metastasis [35] . Mobilization of bone marrow-derived cells (BMDCs) and their recruitment to metastatic niches by tumor-derived VEGF-A, PlGF, TNFa and TGFb is one example. These may act directly on the bone marrow, or induce expression of the pro-inflammatory cytokines such as S100A8 and S100A9 at presumptive sites of metastasis that in turn induce expression of serum amyloid A proteins that recruit BMDC to these sites [43] [44] [45] . The systemic concentration of such tumor-derived factors presumably needs to exceed a threshold before acting to promote stromal progression. The sentinel lymph node would be the first organ to experience concentrations of these factors above threshold levels, as the interstitial fluid draining from the primary tumor to the sentinel node would contain higher concentrations of the factors than the blood. Thus stromal progression in lymph nodes driven by these factors could serve to support and activate disseminated tumors cells in lymph nodes, and for example release them from dormancy. The pre-metastatic induction of lymphangiogenesis in sentinel lymph nodes may be part of this stromal progression [46, 47] , as our own unpublished work indicates that this lymphangiogenesis is necessary for the outgrowth of lymph node metastases but not lung metastases (Quagliata et al., manuscript submitted). Interestingly, VEGF-A not only mobilizes and recruits BMDC to metastatic niches, but is also involved in the regulation of tumor-induced lymphangiogenesis, a process that promotes metastasis to lymph nodes [7, 43, 48] . Thus tumorderived growth factors that induce tumor-induced lymphangiogenesis locally and thereby also promote lymph node metastasis formation may also independently promote metastasis in vital organs through systemic activities [7] . As a general principle, soluble factors produced by tumors could serve in a number of ways to promote metastasis formation in lymph nodes, but independently foster metastasis formation in distant vital organs. In this scenario, lymph node metastases would act as signs of poor prognosis by indicating that primary tumors are producing substantial quantities of metastasis-promoting growth factors.
CTCs and DTCs: representatives of both blood and lymphatic dissemination
The analysis of CTCs and DTCs as cellular surrogates of metastatic progression is growing increasingly important [49] . CTCs may be derived from primary tumors or metastases, and DTCs represent the population of tumor cells from which metastases will develop. The interconnectivity of the blood and lymphatic circulatory systems suggests that the sampling and analysis of CTCs from either compartment should be equally informative, and that DTCs may be derived from CTCs that have circulated through one or both compartments. Due to the difficulty of sampling lymphatic fluid, blood is invariably the routine source of CTCs. By analyzing the properties of CTCs and DTCs, clinical information about the metastatic status of tumor cells regardless of their route of dissemination can be obtained. Such analysis is useful for the prognosis evaluation of cancer patients, for stratification and monitoring of therapy, for the identification of therapeutic targets, and provides new insights into mechanisms relevant for resistance to therapy.
The challenge of picking up cancer cells in the circulation or in the bone marrow is that these cells occur at very low frequency of 1 cell in millions of normal blood and bone marrow cells [50] . Thus, very sensitive and specific methods are needed [51] . We started many years ago to focus on the bone marrow because it can be easily assessed by needle aspiration from the iliac crest, which is a standard diagnostic procedure in leukemia patients. Moreover, the bone marrow is one of the most frequent sites of metastasis in breast cancer, prostate cancer, lung cancer. We screened about 2 million bone marrow cells per patient using an antibody against cytokeratins. Cytokeratins are epithelial cytoskeleton proteins widely used as markers for epithelial tumor cells. They are not expressed on the mesenchymal bone marrow, blood cells or lymph node cells, and they have been introduced more than 20 years ago as a marker for the detection of DTCs [52] . Bone marrow cytospins can be screened by automatic microscope systems (e.g., ARIOL TM ) and photo galleries are available to aid the skilled observer in identifying the cancer cells.
In breast cancer patients at primary diagnosis with no signs of overt metastases, we found that 36 percent already had DTCs in the bone marrow [53] , indicating that tumor cell dissemination is an early process occurring after the establishment of the malignant primary tumor. We could find similar detection rates in prostate cancer patients [54] , and we could show that this is a quite specific test by looking at patients with non-malignant diseases as controls [53] . Why is that interesting? We and others have clearly shown that the detection of DTCs in bone marrow is associated with a worse outcome [55] . Besides being a prognostic test, it might also be used for stratification of therapies that block the interaction of the cancer cells with the bone marrow stroma such as bisphosphonates or inhibitors of RANK ligands.
Approximately 10 years ago the field shifted from detection of cancer cells in the bone marrow (an invasive procedure), to detection of cancer cells in the circulation because it is much easier to collect peripheral blood. Four principles have been employed to capture CTCs [56] . Enrichment based on cell size by filter systems has been used, assuming that the cancer cells are bigger than leukocytes. However, the size of cancer cells can vary in patients. The ability of cancer cells to invade into collagen matrixes has also been used to enrich CTCs. In addition, CTCs can be enriched on the basis of mechanical and physical features such as density or dielectric properties. They can also be enriched by the expression of marker proteins expressed on their surface. The most common marker protein used for this approach is the epithelial cell adhesion molecule (EpCAM). Antibodies directed to this cell surface molecule can be coupled to ferromagnetic particles or on micro-posts in small CTC chips, facilitating the capture of marked CTCs. It is also possible to deplete the surrounding leukocytes using the common leukocyte marker antigen, thereby enriching the tumor cell content. All of these methods have their advantages and disadvantages [51, 56] .
After the enrichment step the tumor cells are still surrounded by hundreds or thousands of leukocytes, and need to be identified. Immunocytochemistry with antibodies against cytokeratins as marker proteins has become a standard technology. Quantitative RT PCR can also be used by amplifying specific mRNAs as markers, for example cytokeratin-19 [57] . The EPISPOT assay where each immunospot corresponds to one tumor cell secreting the marker protein (e.g., PSA or CK19) has also been employed. To date only one system has been cleared by the FDA, the CellSearch TM System. Using a 7.5 mL blood tube, the machine captures EpCAM positive cells using ferromagnetic nanoparticles, and subsequently immunostains them with antibodies against cytokeratins as a tumor marker and the common leukocyte antigen CD45 as an exclusion marker. This automated system allows a highly reproducible automated detection of CTCs [58] , but it has the disadvantage that EpCAM-negative CTCs or CTCs not recognized by the anti-cytokeratin antibodies used in the CellSearch TM System are not detected [59, 60] . The system has been mainly validated in cancer patients with advanced metastatic disease, and has been cleared for breast cancer, colorectal cancer and prostate cancer [61] [62] [63] . Recent studies have focused on lung cancer [64] . Although healthy control individuals are usually free of epithelial cells in their blood, patients with benign inflammatory bowel diseases harbor circulating epithelial cells, which may lead to false-positive ''CTC'' findings [65] .
The real challenge now is to evaluate whether CTC detection is able to detect and monitor micrometastatic disease in patients receiving (neo)adjuvant therapy. The present serum biomarkers used in the clinic are not sensitive enough, and failure of therapy is usually observed late when overt metastases are already established and the chance of the patient being cured is minimal. We therefore performed a neoadjuvant trial with the German breast cancer group. The patients all received chemotherapy, and a subset of them additionally received trastuzumab, an antibody against HER2 which is the most prominent oncogene used as a biological target in breast cancer. We assessed CTCs before and after neoadjuvant therapy using the CellSearch device and observed a reduction in the number of CTC-positive patients from 22 to 11 percent [66] , indicating that there was an impact on the number of CTCs. We are now following up the patients to see whether that also translates into outcome.
We also typed the CTCs with an antibody against HER2 and developed an immunoscoring system for the strength of HER2 expression on CTCs. Since HER2 over-expression can be caused by HER2 gene amplification, we also developed a FISH analysis on top of the CTC analysis to distinguish cells with and without HER2 gene amplification. Interestingly, a significant number of patients with HER2 positive CTCs had HER2-negative primary tumors [66] , suggesting that these patients may profit from HER2-directed therapies. We are now testing this hypothesis in a prospective multicenter randomized trial on breast cancer patients in Germany. Thus, routine pathologic scoring of HER2 status may miss a small subset of cells in the primary tumor that express HER2 and become metastatic. The second interesting observation was that after the antibody therapy we observed HER2 negative CTCs, indicating that these cells can escape the antibody therapy because the tumor cells lack the receptor.
Besides FISH analyses, a more in-depth molecular characterization of CTCs is required to understand the complex biology of disseminating cancer cells. We have developed a system where we place cells obtained by the CellSearch system on a slide, and aspirate single CTCs using a micromanipulator. We then lyse the cells and use the DNA to perform a whole genome amplification, specific PCRs or screening techniques such as comparative genomic hybridization. As an example, we analysed genes relevant for therapy resistance such as KRAS, which is important for resistance against EGFR inhibition. In patients with colorectal cancer, we could find different CTCs that were either wild type or mutated for KRAS. We are now implementing this information in trials using EGFR inhibition to see whether CTC analysis allows us to obtain additional information compared to primary tumor analysis.
In other approaches, RNA expression at the single CTC level has been investigated, in the main using EpCAMenriched CTC fractions. These studies have revealed specific CTC expression signatures which were different from the leukocytes and also only partly overlapping with the primary tumors [67] [68] [69] [70] .
In addition to descriptive analyses, it is very important to perform a functional characterization of CTCs. One of the few available experimental systems is the EPISPOT assay [71, 72] , in which tumor cells are cultured for 2 days during which time they secrete certain marker proteins (e.g., PSA, MUC1 or CK19) which are captured by the antibodies on the culture plates. The cells are then washed off and the secreted proteins are visualized by a second set of antibodies conjugated to fluorochromes. Every cell that secretes a marker protein gives an immunospot, and the number of immunospots equates to the number of CTCs.
Another model that we use are cell lines that are established from breast cancer micrometastases in the bone marrow. These cell lines are CD44 high/CD24 low, which is characteristic of the first cancer stem cell phenotype in solid tumors discovered by Max Wicha and Michael Clarke [73] . Interestingly, these cells also express certain stress response proteins that makes them very adaptable to the hypoxic conditions in the bone marrow [74] . The bone marrow has very hypoxic niches in which stem cells reside, and there is evidence that DTCs can compete with hematopoietic stem cells for these niches [75] . Thus DTCs may be adapted to survive in this particular environment. Although cell lines are arguably artificial models, Balic et al. [76] have shown that most DTCs in breast cancer patients also express the CD44?/CD24-cancer stem cell phenotype.
When epithelial tumor cells lose their intercellular adhesion and become mobile, they may undergo a phenotypic change called epithelial-to-mesenchymal (EMT) transition [77] , which is connected with a loss of epithelial markers (e.g., E-Cadherin and cytokeratins) and an increase of mesenchymal markers (e.g. vimentin). This creates a problem because our current CTC/DTC detection systems are based on epithelial markers, and if DTCs lose these markers we will miss them. Although the relevance of EMT for the progression of cancer patients is still under debate, there is increasing evidence that CTCs with an EMT phenotype exist in patients with breast and prostate cancer [59, 78] .
Conclusions
Although a number of observations over the last two centuries have been interpreted to suggest that lymph node metastases govern the formation of metastasis formation in distant vital organs, more recent findings suggest this may not necessarily be the case. The lymphatics provide a conduit within which tumor cells can circulate that is closely apposed to the blood vasculature, and tumor cells can transit between these two circulatory systems. Prior to overt lymph node metastasis formation, animal models suggest that the metastatic proclivity of CTCs can be enhanced by serial conditioning of the cells in the lymph node microenvironment. Thus at this stage, the lymph node microenvironment could conceivably influence metastasis formation and have a negative impact on clinical outcome. Consistently, the presence of micrometastases in lymph nodes draining primary melanomas correlates with poor prognosis [79] . However, once overt lymph node metastases form, lymphatic channels eventually become blocked until collaterals form to divert lymphatic flow around the blockage [14] . Furthermore, analysis of growth rates of tumors and their metastases suggest that lymph node metastases do not contribute to a metastatic cascade by seeding further metastases in other organs [32, 33] . Largescale randomized clinical trials also suggest there is little if any benefit to patient survival if the draining lymph nodes are removed [1] . Thus these observations suggest that overt metastasis formation in lymph nodes acts as an indicator of poor prognosis. Although much research still needs to be done, the indicator function may be due at least in part to the production of soluble factors by primary tumors that stimulate metastasis formation in both the lymph nodes and in distant organs. Analysis of CTCs and DTCs allows dissemination in both the blood and lymphatic compartments and the development of metastastic properties to be assessed. The information provided by the analysis of CTCs and DTCs provides important clinical information that can guide the therapeutic management of cancer patients, but also gives insights into the biology of metastasis that may lead to new strategies for the prevention of distant metastasis formation, the prime cause of cancer-related deaths.
